Aramis Biotechnologies and the Biologics Manufacturing Centre (BMC) announced they have completed formulation, aseptic fill‑finish, and clinical packaging for Aramis’s seasonal influenza vaccine. The milestone delivers clinical‑grade material for Phase 1/2 trials, meeting regulatory quality and safety requirements. The achievement underscores BMC’s capacity to support Canadian biotech firms with integrated manufacturing services. It positions Aramis’s plant‑based vaccine platform for further development and potential market entry.
Novo Nordisk and Aspect Biosystems have entered a new partnership phase to develop curative cellular medicines for diabetes. Aspect will acquire Novo Nordisk's stem‑cell‑derived islet and hypoimmune technologies and lead development, manufacturing, and commercialization, while Novo Nordisk retains rights to...
In 2025 the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) tackled five critical animal‑health challenges, from a first‑record H5N1 outbreak in dairy cattle to a world‑first chlamydia vaccine for endangered koalas. Researchers demonstrated natural immunity in infected cows,...